Point72 discloses 3.8% Design Therapeutics (DSGN) stake totaling 2.37M shares
Point72 Asset Management, along with Point72 Capital Advisors, Inc. and Steven A. Cohen, has reported a beneficial ownership of 2,366,453 shares of Design Therapeutics, Inc. (DSGN) common stock, which represents 3.8% of the class, as of June 30, 2026. The filing indicates that while they hold shared voting and dispositive power over these shares through an investment fund, they do not claim sole power. This disclosure, made via an amended SCHEDULE 13G/A, confirms their ownership is 5 percent or less of the company.
Design Therapeutics (DSGN): Sirenia Capital discloses 9.5% beneficial ownership stake
Sirenia Capital Management LP and Alex Silverstein have reported a 9.5% beneficial ownership stake in Design Therapeutics, Inc. (DSGN), totaling 5,963,936 shares, which includes shares issuable from call options. This disclosure was made in a Schedule 13G filing, indicating a passive investment purpose rather than an intent to influence control. The filing details shared voting and dispositive power over these shares, with SILV Fund, Ltd. also having rights to dividends or sale proceeds from over 5% of the outstanding common stock.
Design Therapeutics, Inc. $DSGN Shares Bought by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP significantly increased its stake in Design Therapeutics (NASDAQ:DSGN) by 45.0% in Q1, now owning 431,840 shares valued at $4.59 million. Other institutional investors also adjusted their holdings in the company. Design Therapeutics reported better-than-expected Q2 earnings and has an average "Moderate Buy" rating from analysts with an average price target of $16.50.
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages
Design Therapeutics, Inc. (NASDAQ:DSGN) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 12-month price target of $16.50. The stock recently opened at $14.33, trading above its 50-day and 200-day moving averages, and institutional investors own over 56% of the company. The biopharmaceutical company focuses on developing small molecule therapeutic drugs for genetic diseases using its GeneTAC platform.
Design Therapeutics, Inc. $DSGN Shares Purchased by Sei Investments Co.
Sei Investments Co. significantly increased its stake in Design Therapeutics, Inc. (NASDAQ:DSGN) by 152.6% in the first quarter, now holding 133,203 shares valued at approximately $1.42 million. Institutional investors collectively own 56.64% of the company. Despite reporting a quarterly EPS of negative $0.32, beating estimates, the stock carries a "Moderate Buy" consensus rating from analysts with an average price target of $16.50.
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Design Therapeutics Inc (DSGN), noting its current earnings forecast score is 8.86, ranking 47 out of 387 in its industry. Analysts have set an average price target of $12.50, with a majority recommending a "Buy" for the stock. The company's previous quarter's EPS was -$0.29, beating the market expectation of -$0.32, and the next quarter's EPS is projected to be -$0.36.
Renaissance Technologies LLC Buys 121,100 Shares of Design Therapeutics, Inc. $DSGN
Renaissance Technologies LLC increased its stake in Design Therapeutics, Inc. (NASDAQ:DSGN) by 42.2% in the first quarter, purchasing an additional 121,100 shares, bringing its total holdings to 408,200 shares valued at approximately $4.34 million. Other institutional investors have also adjusted their positions in the company, which currently has 56.64% institutional ownership. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $16.50, and the company recently beat quarterly earnings estimates.
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22
Craig-Hallum has reiterated its Buy rating for Design Therapeutics (DSGN.US) and maintained its target price at $22. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Design Therapeutics Reports $20.2 Million Q2 Net Loss, Updates RESTORE-FA Trial
Design Therapeutics reported a net loss of $20.2 million for Q2 2024, down from $25.2 million in the same period last year. The company provided an update on its RESTORE-FA Phase 1b clinical trial for Friedreich's ataxia, noting positive clinical data continues to emerge. They anticipate presenting results from the 28-day multiple ascending dose portion of the trial in Q4 2024.
Design Therapeutics : Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Design Therapeutics announced updates on its RESTORE-FA clinical program, modifying the trial to focus on a 1 mpk dose with 12-week data expected in Q1 2027. The company also initiated dosing for its DT-818 in a Phase 1 trial for myotonic dystrophy type 1 and reported second quarter 2026 financial results, including a net loss of $20.2 million and a strong cash position of $207.4 million. Delays in DT-168 supply pushed FECD data to 2027, while preclinical work continues for Huntington's disease.
Design Therapeutics Q2 Net Loss Narrows
Design Therapeutics reported a narrowed net loss for the second quarter, although it did not provide specific figures in the provided document. The company's financial performance indicates an improvement in its loss compared to the previous period.
Design Therapeutics, Inc. 2Q 2026: Net loss $(20,165)K, EPS $(0.32) — 10-Q Summary
Design Therapeutics, Inc. (DSGN) reported a net loss of $(20,165)K and diluted EPS of $(0.32) for Q2 2026, with cash and investments totaling $207.4M, providing over 12 months of runway. The company highlighted clinical progress in its RESTORE-FA Phase 1/2 trial, pipeline expansion across multiple disease areas, and favorable safety profiles for its drug candidates. An improved formulation of DT-216 (P2) also showed better human pharmacokinetics, leading to a modified trial design and registrational planning.
Design Therapeutics posts Q2 loss, updates clinical trials
Design Therapeutics Inc. reported a net loss of $20.2 million for Q2 2026, or $0.32 per share, with total cash and investments at $207.4 million. The company updated its RESTORE-FA trial for Friedreich ataxia, specifying endogenous blood FXN protein percent change as the primary efficacy endpoint and exploring a higher dose. It also initiated a Phase 1 trial for myotonic dystrophy type 1 and expects data for its Fuchs endothelial corneal dystrophy trial in 2027 due to supply delays.
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Design Therapeutics reported its second-quarter 2026 financial results and provided updates on its clinical programs. The company highlighted progress in its RESTORE-FA trial for Friedreich ataxia, initiating patient dosing for DT-818 in myotonic dystrophy type 1, and advancing preclinical work for Huntington's disease. Design Therapeutics ended the quarter with $207.4 million in cash and securities, providing a strong financial runway.
Design Therapeutics reports $20.2M Q2 net loss, $207.4M cash as RESTORE-FA advances
Design Therapeutics reported a net loss of $20.2 million for Q2 2026, holding $207.4 million in cash, cash equivalents, and investment securities. The company provided updates on its clinical programs, including the advancement of RESTORE-FA (DT-216P2) with an expected registrational plan update in Q4 2026 and initiation of a Phase 1 trial for DT-818 in myotonic dystrophy type 1. Other programs like DT-168 for Fuchs endothelial corneal dystrophy faced minor delays.
DSGN|Design Therapeutics Inc|Price:11.860|Chg%:-0.020
This article provides a comprehensive stock analysis of Design Therapeutics Inc (DSGN) by TradingKey. It highlights the company's relatively weak fundamentals but high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Despite institutional confidence and a strong "Buy" rating from multiple analysts, the stock has shown weak market performance and is expected to trend down in the medium term, trading sideways between support and resistance levels.
Design Therapeutics Inc (DSGN) Institutional Confidence
Design Therapeutics Inc (DSGN) has an institutional shareholding score of 5.00, placing it 132nd out of 385 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently decreased by 8.26% quarter-over-quarter to 61.89%. Steven Cohen is the largest institutional shareholder, holding 2.61 million shares, which represents 4.36% of the shares outstanding, despite a 14.84% decrease in his holdings.
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Design Therapeutics Inc (DSGN), highlighting its current earnings forecast score of 8.86 and an average price target of $12.50 based on 7 analyst ratings. Most analysts rate DSGN as a "Buy" for its stock. The report also includes past and projected EPS figures and a peer comparison within the Biotechnology & Medical Research industry.
Design Therapeutics Inc (DSGN) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Design Therapeutics Inc (DSGN), detailing various financial metrics related to volatility, drawdown, and liquidity. Key figures include a Beta vs S&P 500 index of 1.66, a 240-Day Volatility of +84.43%, and a 5-year maximum drawdown of +92.22%. The report highlights both positive and negative daily returns over different periods, offering insights into the stock's historical performance and risk profile.
DSGN|Design Therapeutics Inc|Price:11.955|Chg%:+0.175
Design Therapeutics Inc. (DSGN) is a biotechnology company focused on developing gene-targeted chimera therapeutic candidates for diseases caused by inherited nucleotide repeat expansion mutations. The company's stock is currently priced at $11.89 with a market cap of $718.13M, showing high growth potential despite relatively weak fundamentals. Analysts have rated DSGN as a "Buy" with a target price of $21.00, indicating a 78.27% upside.
We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate
This article analyzes Design Therapeutics' cash burn rate, concluding that despite a high burn, the company has enough cash to last for over two years. The analysis considers the company's current cash and short-term investments against its cash burn from operations and investing activities. While acknowledging the need for future funding, the author suggests the current burn rate is manageable in the short term.
Design Therapeutics (DSGN) Leerink Global Healthcare Conference 2026 Summary
Design Therapeutics (DSGN) presented a summary of their Leerink Global Healthcare Conference 2026 participation, highlighting key program updates and their financial position. The company anticipates 12-week dosing data from their RESTORE-FA study in the second half of the year, with ongoing multiple ascending dose studies for safety. Their pipeline includes DT-818 for DM1, and an exploratory biomarker study for Fuchs' corneal dystrophy, all supported by a cash position exceeding $200 million, providing runway into 2029.
Design Therapeutics (DSGN) Q1 2026 earnings summary
Design Therapeutics (DSGN) reported its Q1 2026 earnings, detailing advancement in four GeneTAC® molecule programs for severe monogenic disorders, including Friedreich Ataxia (FA), Fuchs Endothelial Corneal Dystrophy (FECD), Myotonic Dystrophy Type 1 (DM1), and Huntington's Disease (HD). The company's lead FA candidate, DT-216P2, progressed to Phase 1/2 after the FDA lifted a clinical hold, with key data readouts for FA and FECD programs expected in H2 2026. Financially, DSGN holds $222.8 million in cash reserves as of March 31, 2026, projected to fund operations into 2029, despite a net loss of $17.6 million for the quarter.
Design Therapeutics (DSGN) Jefferies London Healthcare Conference 2024 Summary
Design Therapeutics (DSGN) presented at the Jefferies London Healthcare Conference 2024, highlighting its strategic vision for pioneering small molecule genomic medicines for monogenic diseases. The company detailed pipeline progress, including plans to advance programs for Friedreich ataxia and Fuchs endothelial corneal dystrophy into clinical trials, with a cash runway extending into 2029. Scientific insights emphasized the efficacy of their GeneTAC molecules in restoring protein expression and targeting toxic RNA foci.
Design Therapeutics (DSGN) Proxy filing Summary
Design Therapeutics (DSGN) has summarized its proxy filing, detailing an Annual Meeting scheduled for June 9, 2026. Shareholders will vote on electing a Class II director and ratifying Ernst & Young LLP as the independent auditor for fiscal year 2026, with proxy materials available online. The company emphasizes board diversity, with 43% of directors being women or racially/ethnically diverse, and provides instructions for voting and meeting attendance.
Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien
The Myotonic Dystrophy market is projected to reach approximately USD 89 million in 2023 and grow at an 18.4% CAGR through 2036, driven by increased disease awareness, genetic research advancements, and a robust clinical pipeline. Several companies, including Avidity Biosciences and Dyne Therapeutics, are developing therapies, with key clinical updates and regulatory designations occurring between 2025 and 2026. The report by DelveInsight offers insights into the market's epidemiology, drug uptake, and pipeline activities across the US, EU5, and Japan.
If You Invested $1,000 in Design Therapeutics, Inc. (DSGN)
This article examines the historical performance of investing $1,000 in Design Therapeutics, Inc. (DSGN) over various periods, showing substantial gains in the last year but losses over longer terms. It also provides a detailed overview of the company, a clinical-stage biotechnology firm, its GeneTAC® platform, lead clinical programs for Friedreich ataxia and Fuchs endothelial corneal dystrophy, and its expansion into myotonic dystrophy type-1 and Huntington’s disease. DSGN focuses on developing treatments for serious degenerative genetic diseases by modulating gene expression.
Price to sales forward of Design Therapeutics, Inc. – NASDAQ:DSGN
This article displays the "Price to sales forward" financial metric for Design Therapeutics, Inc. (NASDAQ: DSGN). The content includes the company's stock symbol, market, and a brief mention of the financial data period, value, and change.
Price to earnings forward of Design Therapeutics, Inc. – NASDAQ:DSGN
This page from TradingView displays financial information for Design Therapeutics, Inc. (NASDAQ: DSGN), specifically focusing on its forward price-to-earnings ratio. The content indicates that the market was closed at the time of access, with no trades occurring. The page also lists various data providers, copyright information, and links to other TradingView features and resources.
Design Therapeutics (Nasdaq:DSGN) - Stock Analysis
This article provides a stock analysis of Design Therapeutics (DSGN), highlighting its current market performance, risk factors, and pipeline developments. The company, a clinical-stage biopharmaceutical firm focusing on genetic diseases, shows significant stock growth over the past year but faces financial challenges with unprofitability and forecasted earnings decline. Key developments include clinical trials for Myotonic Dystrophy Type-1 and Friedreich Ataxia, with both positive biomarker data and new risk assessments impacting investor outlook.
Design Therapeutics begins DM1 trial for DT-818, aims at genetic cause
Design Therapeutics (Nasdaq: DSGN) has initiated patient dosing for its Phase 1 multiple-ascending dose (MAD) trial of DT-818, a GeneTAC small molecule, for adults with myotonic dystrophy type-1 (DM1). DT-818 is designed to address the underlying genetic cause of DM1 by selectively reducing the transcription of the mutant DMPK allele. Data from this open-label study, which will assess safety, tolerability, pharmacokinetics, and pharmacodynamics, is anticipated in 2027.
Design Therapeutics begins dosing DM1 drug in phase 1 trial By Investing.com
Design Therapeutics (NASDAQ:DSGN) has initiated patient dosing for its DT-818 drug in a Phase 1 clinical trial for adults with myotonic dystrophy type-1, leading to a 6.7% surge in its stock. The company anticipates reporting data from this trial in 2027 and continues to advance other GeneTAC platform-based therapies for various diseases. Despite trading above its Fair Value, the company maintains a strong financial position, recently surpassing Q1 2026 earnings per share forecasts and showing positive data in another clinical trial for Friedreich ataxia, leading RBC Capital to raise its price target.
Design Therapeutics stock rises on Phase 1 trial dosing start By Investing.com
Design Therapeutics Inc. (NASDAQ:DSGN) shares rose in premarket trading after the company announced the initiation of patient dosing in its Phase 1 trial for DT-818. This GeneTAC small molecule aims to treat myotonic dystrophy type-1 (DM1) by targeting the underlying genetic cause of the disease. The company expects to report data from this safety and tolerability study in 2027.
Design Therapeutics begins dosing DM1 drug in phase 1 trial
Design Therapeutics (NASDAQ:DSGN) has commenced patient dosing in a Phase 1 clinical trial for DT-818, a potential treatment for myotonic dystrophy type-1 (DM1). The company's stock surged on the news, having already seen significant gains over the past year. DT-818 is designed to reduce the mutant DMPK allele associated with the progressive neuromuscular disease, and Design Therapeutics expects to release trial data in 2027.
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
Design Therapeutics has initiated patient dosing for its Phase 1 multiple-ascending dose (MAD) clinical trial of DT-818, a GeneTAC® small molecule for Myotonic Dystrophy Type-1 (DM1). DT-818 is designed to address the genetic cause of DM1 by selectively reducing the transcription of the mutant DMPK allele. The company anticipates reporting data from this study in 2027.
Design Therapeutics spikes as RBC upgrades on an eventful 2026
Design Therapeutics (NASDAQ:DSGN) saw its shares rise after RBC Capital upgraded the stock, citing upcoming catalysts and a potentially "eventful" 2026. The upgrade reflects optimism about the company's future prospects and clinical developments.
Design Therapeutics spikes as RBC upgrades on an eventful 2026
Design Therapeutics (DSGN) shares surged after RBC Capital Markets upgraded the stock. The upgrade was based on expectations for an "eventful 2026," particularly regarding the company's DM1 program, which RBC now believes has a higher likelihood of success.
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Small Cap Comp Growth Benchmark
Design Therapeutics, Inc. (DSGN) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is among several recent updates for the company within the Russell indices, including additions to the Russell 2500 Growth Benchmark and Russell Microcap Growth Benchmark, and exclusions from the Russell 2000 Value Benchmark and Russell Microcap Value Benchmark Index. The biotech company is focused on developing GeneTACT molecules for diseases caused by inherited nucleotide repeat expansion mutations, with therapies in clinical trials for Friedreich ataxia and Fuchs Endothelial Corneal Dystrophy (FECD).
Design Therapeutics, Inc.(NasdaqGS: DSGN) dropped from Russell 2000 Value Benchmark
Design Therapeutics, Inc. (NasdaqGS: DSGN) has been removed from the Russell 2000 Value Benchmark, as announced on June 29, 2026. This news comes alongside several other Russell index adjustments for the company, including being added to the Russell Small Cap Comp Growth, Russell 2500 Growth, Russell Microcap Growth, and Russell 2000 Growth benchmarks, while also being dropped from the Russell Microcap Value Index. The biotechnology company focuses on developing GeneTACT molecules for diseases caused by inherited nucleotide repeat expansion mutations.
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 3000E Growth Benchmark
Design Therapeutics, Inc. (NasdaqGS: DSGN) has been added to the Russell 3000E Growth Benchmark. The company specializes in developing GeneTACT molecules—small-molecule gene-targeted chimera therapeutic candidates designed for diseases caused by inherited nucleotide repeat expansion mutations. Design Therapeutics is currently advancing programs for Friedreich ataxia and Fuchs Endothelial Corneal Dystrophy, with both DT-216P2 and DT-168 in clinical trials.
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
Design Therapeutics (NASDAQ:DSGN), a loss-making company, saw its share price soar by 274% over the last year. Despite an increase in cash burn to US$54 million, the company maintains a robust cash runway of 4.1 years based on its US$223 million cash reserves. Analysts believe Design Therapeutics could easily raise additional capital if needed, given its cash burn represents only 6.5% of its market capitalization.
Design Therapeutics, Inc. Actuals & Estimates (NASDAQ:DSGN)
This article provides an overview of Design Therapeutics, Inc. (DSGN) stock performance, financial estimates, and analyst forecasts. It includes details on the current stock price, volatility, market capitalization, historical highs and lows, and upcoming earnings reports, along with frequently asked questions about investing in DSGN.
DSGN Forecast — Price Target — Prediction for 2027
This article provides an outlook on Design Therapeutics, Inc. (DSGN) stock, including analyst price targets, historical performance, and financial data. Analysts predict a max estimate of $22.00 and a min estimate of $20.00 for DSGN. The company's stock has shown significant growth over the past year, with a 237.97% increase, and has a market capitalization of $839.42 million.
Design Therapeutics Inc (DSGN) Institutional Confidence
Design Therapeutics Inc (DSGN) has an institutional shareholding score of 5.00, ranking 132nd in the Biotechnology & Medical Research industry, with institutional shareholding at 61.89%, a decrease of 8.26% quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 2.61 million shares, representing 4.36% of shares outstanding.
Design Therapeutics Inc (DSGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Design Therapeutics Inc (DSGN), detailing its price momentum, support and resistance levels, and various technical indicators like MACD, RSI, and moving averages. As of June 18, 2026, DSGN has a price momentum score of 9.66 and is showing a "Buy" signal based on its moving averages and other technical indicators, despite some indicators showing neutral or sell signals. The stock is currently trading between resistance at $13.46 and support at $10.65, suggesting suitability for range-bound swing trading.
Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $21
Oppenheimer has reiterated its Buy rating for Design Therapeutics (DSGN.US), maintaining a target price of $21. This indicates continued analyst confidence in the company's prospects.
Design Therapeutics Inc (DSGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey attempts to provide a revenue breakdown for Design Therapeutics Inc (DSGN), covering its business segments, regional revenue, and profit contribution. However, the company has not disclosed the relevant data, leading the report to state that this information is currently unavailable. The page also includes current stock performance and general company information for DSGN.
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Design Therapeutics Inc (DSGN), highlighting its current earnings forecast score, average price target of $12.50, and analyst ratings. Based on 7 analysts, most support a "Buy" trend for the stock. The article also touches on past and future EPS expectations.
Design Therapeutics (DSGN) grants director David Shapiro 30,000 options
Design Therapeutics (DSGN) has granted director David Shapiro 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months starting from June 9, 2026, and will be fully vested by the company’s next annual meeting of stockholders. This compensation-related award was reported in an SEC Form 4 filing on June 11, 2026.
Design Therapeutics (DSGN) grants George Simeon 30,000 stock options at $10.55
Design Therapeutics (DSGN) director George Simeon was granted 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months after June 9, 2026, or fully by the company's next annual stockholder meeting. This transaction was reported in a Form 4 SEC filing, indicating a compensation-related award rather than an open-market purchase or sale.
